Chatham-based Everett Laboraties Inc., a subsidiary of Spain-based Exeltis, announced Monday its acquisition of Quinnova Pharmaceuticals from Bridgewater-based Aneal Enterprises LLC. Terms of the deal were not disclosed.
According to the announcement, the acquisition will result in the strategic expansion of Everett into the fast-growing U.S. dermatology market. As a member of the Exeltis family, the acquisition will allow Quinnova to leverage extensive resources and capabilities in research and development, marketing strategy, intellectual property and business development worldwide. This broad-based support will enable Quinnova to be positioned to accelerate growth and development of its product portfolio and development pipeline.
Stay informed: Subscribe to free NJBIZ newsletters
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.View Comment Policy